Plus Capital Lease Obligations from 2010 to 2025
| PSTV Stock | USD 1.16 0.36 23.68% |
Capital Lease Obligations | First Reported 2018-09-30 | Previous Quarter 142 K | Current Value 108 K | Quarterly Volatility 455.5 K |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Capital Lease Obligations |
Latest Plus Therapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Plus Therapeutics over the last few years. Plus Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Plus Therapeutics asset purchases. For example, Plus Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Plus Therapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Plus Therapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Plus Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 183,769 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 148.82 | |
| Mean Deviation | 206,740 | |
| Median | 0.00 | |
| Standard Deviation | 273,486 | |
| Sample Variance | 74.8B | |
| Range | 913K | |
| R-Value | 0.53 | |
| Mean Square Error | 57.6B | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | 30,443 | |
| Total Sum of Squares | 1.1T |
Plus Capital Lease Obligations History
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 235.8 K | 294.6 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.